Investment
Features
FeesSafety
Academy
More
Pluang+

Vertex Pharmaceuticals' new drug Povetacicept may get FDA approval by Nov for autoimmune disease treatment.

Analyst Insights
24 Jun 2026
Seeking Alpha
View Source
Neutral
pluang ai news

Vertex Pharmaceuticals is expecting FDA approval for Povetacicept by November 30 to treat immunoglobulin A nephropathy, an autoimmune disease. However, sales of their other drugs, Journavx and Casgevy, have declined by 11.2% year-on-year, generating $71.9 million in Q1. This mixed performance balances the risk and reward for Vertex's stock. The company’s success extends beyond cystic fibrosis treatments, but demand softness for some products tempers growth expectations.

More News (VRTX)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App